Alteration Earth PLC (to be renamed Pri0r1ty Intelligence Group PLC) announced the admission of its entire issued share capital to trading on the AIM Market of the London Stock Exchange today
Alteration Earth PLC (to be renamed Pri0r1ty Intelligence Group PLC) announced the admission of its entire issued share capital to trading on the AIM Market of the London Stock Exchange today
Following the successful completion of its recent fundraising, Asiamet (ARS) provided a further update on optimisation works being completed in preparation for project financing on the BKM Copper Project located in Central
Mendell Helium (AQSE:MDH) provided an overview of M3 Helium Corp.’s assets following a visit in October 2024 by Nick Tulloch, Chief Executive Officer of the Company, to Kansas, USA.
Global (GBP) announced its financial results for the year ended 30 June 2024. GBP said it was filled with optimism about the transformative journey Global Petroleum is undertaking.
Helix Exploration (HEX), the helium exploration and development company focused on helium deposits within the ‘Montana Helium Fairway’, announced the completion of construction work on access road and drill pad at
The AIM All-Share Index dropped 2.1% as concerns grew ahead of Labour Chancellor Rachel Reeves’s upcoming Autumn Budget.
“No Higher Taxes For Working (Class) People”
OptiBiotix Health (OPTI) announced that Graham Myers, Finance Director of the Company, has notified the Company that he will step down from the Board on 30 November 2024. David Blain will
Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, confirms that King’s College Hospital (KCH) will be running a pilot of its Steriwave® light-activated antimicrobial technology.
Yesterday MetalNRG (MNRG), the natural resources company, announced that it has signed a binding sale and purchase agreement to acquire the entire issued share capital of Compagnie Minière de Oumejrane from Managem
Avacta Group (AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces its unaudited interim results for the six months ending 30 June 2024 with recent progress against
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health is extremely disappointed to note the Requisition for a General Meeting which has been made by